Background {#Sec1}
==========

The use of intensity-modulated radiation therapy (IMRT) for post-operative patients with uterine cervical cancer allows for a reduction in unwanted doses to healthy organs \[[@CR1]--[@CR4]\] and radiation-related complications \[[@CR5], [@CR6]\], compared with three-dimensional conformal radiotherapy (3DCRT). For instance, some studies reported lower doses to the bladder, rectum, and bowel with IMRT than with 3DCRT \[[@CR1], [@CR2]\]. Roeske et al. reported that the bowel dose in IMRT could be reduced by approximately 50% compared with that in 3DCRT \[[@CR1]\]. The NRG Oncology/RTOG 1203 trial aimed to assess acute toxicity and quality of life during treatments with 3DCRT and IMRT for patients with cervical and endometrial cancer. In 2018, it was reported that IMRT has significantly less gastrointestinal (GI) and urinary toxicity than 3DCRT \[[@CR7]\].

In 2017, the Japan Clinical Oncology Group (JCOG) started a multicenter clinical trial for high-risk postoperative patients with uterine cervical cancer using IMRT, called JCOG1402 \[[@CR8], [@CR9]\]. The primary endpoint is to confirm the non-inferiority of concurrent chemoradiotherapy using IMRT compared with the historical control data of 3DCRT-CCRT \[[@CR10]\] in terms of 3-year relapse-free survival (RFS). The secondary endpoints are overall survival, local RFS, proportion of ≥ grade 3 late lower GI toxicity, proportion of limbs with edema (lower), adverse events, and serious adverse events.

According to the JCOG1402 protocol \[[@CR9]\], participating institutions shall meet the following requirements for credentials before enrolling the patients: (i) the institution has performed whole-pelvis IMRT for more than five patients in clinical practice; (ii) institutional treatment accuracy shall be confirmed to be within a 3% dose difference and positional differences of 3 mm for the radiation field, which is independently assessed by the Medical Physics Working Group (MPWG) of the Radiation Therapy Study Group (RTSG) in the JCOG \[[@CR11], [@CR12]\]; and (iii) dummy-run: the institution shall submit two cases of treatment planning in postoperative uterine cervical cancer. These treatment plans are assessed by central review to ensure they are appropriate for IMRT treatment planning.

Our purpose is to assess the compliance with treatment planning in a dummy-run for JCOG1402, and the dummy-run in this study will provide helpful information on delineation and planning for the participating institutions in order to standardize IMRT planning for postoperative uterine cervical cancer.

Methods {#Sec2}
=======

Protocol design {#Sec3}
---------------

A working group (WG) on postoperative IMRT for uterine cervical cancer was formulated in the RTSG of the JCOG in April 2013. The WG collected information on the clinical concerns about treatment protocols, delineation, immobilization, optimization techniques, prescribed dose, required dose distribution, patient setup, and bladder volume management, and held extensive discussions about establishing an IMRT protocol for a prospective clinical trial JCOG1402 \[[@CR13]\]. The protocol was described as follows. The clinical target volumes (CTV) and organ at risks (OARs) in the JCOG1402 protocol were to be delineated according to the CTV contouring guidelines \[[@CR14], [@CR15]\], and RTOG guidelines of the OARs \[[@CR16]\]. The 1402 protocol contains the pictorial atlas for the CTVs as well as the OARs. The CTV includes CTV vaginal cuff and paracolpium and subclinical lymph node CTV. The bowel bag, an imaginary structure that resembles the peritoneal cavity and was used to surrogate bowel dose, was delineated instead of the actual bowel loop because assessing the dose to the bowel loop itself is challenging owing to internal organ movement during treatment fractions. The vagina cuff planning target volume (PTV) margin will be adequate to cover the geometrical uncertainty due to large inter-fractional movements. According to our previous report \[[@CR17]\], a geometrical margin was proposed to define the vaginal cuff PTV; 0.5, 1.0, and 1.5 cm in the right--left (RL), superior--inferior (SI), and anterior--posterior (AP) direction, respectively, based on full bladder computed tomography (CT) images. Management of the daily bladder volume is essential to minimize inter-fractional variations in bladder volumes or vaginal cuff movements. In addition, a full bladder preparation pushes the small bowel away from the treated region within the pelvis, which results in reduction of the bowel dose. A dose covering 50% of the PTV of 50.4 Gy in 28 fractions was applied to both the nodal and the vaginal cuff PTV. The JCOG1402 dose and dose-volume criteria were derived with consideration of variations of dosimetric parameters in IMRT from the five representative domestic institutions and expert opinions (Table [1](#Tab1){ref-type="table"}).Table 1Dose and dose-volume criteria for the target volumes and organs at risk. 100% indicates the prescribed dose of 50.4 GyStructureStructure namePer protocolAcceptable variationBodyGlobal D~max~\< 115%\<120%PTVPTVD~50%~=100%--D~98%~\>90%\>85%D~95%~\>95%\>90%D~2%~\<110%\<115%Overlap between PTV andbowel bagOL_PTV_BowelD~max~\<105%\<110%RectumRectumV~40\ Gy~\<85%\<95%V~50\ Gy~\<40%\<60%D~max~\<110%\<120%BladderBladderV~45\ Gy~\<50%\<70%D~max~\<110%\<120%Bowel bagBowel bagV~40\ Gy~\<40%\<50%Pelvic bonesPelvic bonesV~10\ Gy~\<85%\<95%V~40\ Gy~\<30%\<50%Femoral jointFemoral jointV~30\ Gy~\<40%\<60%Abbreviations: *D*~*max*~ the maximum dose, *D*~*x%*~ dose covering x% of the volume of the organ, *V*~*y\ Gy*~ volume receiving y Gy

As shown Fig. [1](#Fig1){ref-type="fig"}, the WG also discussed the ideal dose distribution for the three dose levels: (a) 95%, (b) 105%, and (c) 40 Gy. The 95% dose level should cover the whole PTV, and a cold spot less than 95% should not develop inside the primary lesion, i.e., the vaginal cuff, to prevent vaginal recurrence because 3DCRT achieves an excellent uniform dose inside the target volume. Regarding toxicity, 105% of the prescribed dose inside the bowel, including the overlap region of the PTV and the bowel bag, should be avoided. Additionally, the bowel and bladder should be spared to form a horseshoe shape at a dose level of 40 Gy. Information such as the required dose distributions, was provided to the participating institutions for dummy-run tests. The patient setup technique was based on bony structures, and cone-beam CT scans were performed to assess the inter-fractional displacements in the bladder, rectum, and bowel.Fig. 1JCOG1402 protocol guidelines for ideal dose distributions at a dose level of (**a**) 95% (green), (**b**) 105% (pink), and (**c**) 40 Gy (cyan) with the vaginal cuff and nodal PTV (red)

The clinical trial JCOG1402 was approved by the Institutional Ethical Review Board of the National Cancer Center Hospital (Approval number: 2015--359) and was performed in accordance with the ethical standards stipulated in the 1964 Declaration of Helsinki and its later amendments.

Dummy-run {#Sec4}
---------

We prepared two anonymized typical cases from the post-hysterectomy cervical cancer CT dataset from the 1st author's institution. Both cases had vaginal markers for the definition of the CTV vaginal cuff, and case 2 had a moderate amount of ascites. The anonymized CT dataset was then sent to the 47 institutions, and the delineation and IMRT planning were conducted according to the JCOG1402 protocol. The 47 institutions conducted IMRT plans (delineations and dose calculations) for two cases while referring to the JCOG 1402 protocol including the pictorial atlas and the dose constraints. Between November 2016 and June 2018, dummy-run meetings were held eight times, 94 treatment plans including the two cases sent to the 47 institutions were assessed via a central review by the JCOG1402WG. Regarding assessment of inter-observer variation for delineations of the CTV, MIM maestro (MIM Software Inc., OH, USA) was used to calculate the Dice similarity coefficient (DSC) \[[@CR18]\] and the Hausdorff distance (HD) \[[@CR19]\].

The assessed categories in the central review are summarized in the Additional file [2](#MOESM2){ref-type="media"}: Table S1. These are categorized as follows: (1) Delineation: (a) the nodal and (b) CTV vaginal cuff (c) CTV--PTV margin, and (d--f) rectum, bowel bag, and pelvic bones; (g) dose distribution; and (h) dose and dose-volume criteria for each structure. The definition of major deviations in this dummy-run was determined to be deviations from delineation of the nodal and CTV vaginal cuff and/or the ideal dose distribution. If major deviations are observed, the institutions will be required to revise and improve the treatment plans.

Results {#Sec5}
=======

Dummy-run {#Sec6}
---------

Figure [2](#Fig2){ref-type="fig"} shows the numbers of deviation as a function of the categories. The total number of observed deviations for case 1 and 2 was 125 and 169, respectively. On average, 3 and 4 deviations per treatment plan were determined. The deviations related to the CTV delineation accounted for approximately 50% of the total deviations. Table [2](#Tab2){ref-type="table"} shows details of the total deviations shown in Fig. [2](#Fig2){ref-type="fig"}. For nodal CTV, significant deviation in the caudal direction was observed in two cases. In the conventional 3DCRT planning, field edges are created with multi-leaf collimators based on the bony structure. Delineation of the obturator lymph node area near the superior part of the obturator foramen may not be familiar to physicians in some institutions. For CTV vaginal cuff, frequent deviation was observed in the anterior, posterior, cranial, and lateral borders, while less deviation was noticed in the caudal direction. The most frequent deviation was inadequate anterior margins of the CTV vaginal cuff. In such cases, the anterior margin should have been at the posterior border of the bladder or retropubic pad of fat. In some cases, the posterior border of the CTV vaginal cuff seemed inappropriate, and it should have been the anterior border of the mesorectal fascia or anterior wall of the rectum. Some institutions did not measure distance from the vaginal marker/gauze, as noted in the Additional file [2](#MOESM2){ref-type="media"}: Table S1. An unnecessarily large caudal margin with a maximum difference of 2.4 cm was observed for one institution.Fig. 2Categories of the obtained deviations from the protocol for 94 treatment plans including two cases from the 47 institutionsTable 2Gathering major pitfalls of two cases among 94 treatment plans from the 47 institutions through the dummy-run testItemNo. of deviationsContents (*N* = 94)Nodal CTV 27Caudal margin of the obturator lymph node area is the superior part of the obturator foramen. 14Caudal margin of the presacral lymph node area is the lower level of S2 or cranial section of the piriform muscle. 13Adipose connective tissue between lateral surface of vertebral body and psoas muscle is included in the CTV. 13Caudal margin of the external iliac lymph node area is the superior aspect of the femoral head. 5Cranial margin of the common iliac lymph node area is aortic bifurcation. 2Bone or muscle is excluded from the CTV. 9OthersCTV vaginal cuff 19Anterior margin of the CTV vaginal cuff is the posterior border of the bladder or retropubic pad of fat. 16Posterior margin of the CTV vaginal cuff is the anterior part of the mesorectal fascia or anterior wall of the rectum. 13Cranial margin of the CTV vaginal cuff is 1--1.5 cm cranial from the most cranial vaginal marker/gauze. 11Lateral margin of the CTV vaginal cuff is the medial edge of the internal obturator, piriformis, coccygeus, iliococcygeus, or puborectalis muscle; the ishiorectal fossa should be excluded from the CTV vaginal cuff. 4Caudal margin of the CTV vaginal cuff is 3--4 cm caudal from the most cranial vaginal marker/gauze or at lowest level of the obturator foramen, whichever is lower.Bowel bag 9Cranial margin in the protocol was not adhered to, leading to inaccuracy of dosimetric evaluation. 7A part of the rectum was included. 7Caudal margin was inadequate, and it should be the lowest part of the bowel. 3Bladder should be excluded from the bowel 17Othersf) Pelvic bone 13Delineation region in the protocol was not adhered to, leading to inaccuracy of dosimetric evaluation. 10Bone marrow and intervertebral disc were not partially included, leading to inaccuracy of dosimetric evaluation for hematotoxicity. 16Othersg) Dose distribution 10Insufficient 95% dose coverage. 6Insufficient 105% dose coverage. 10Insufficient dose sparing of 40 Gy.

Figure [3](#Fig3){ref-type="fig"} shows the 47 CTVs in case 1, with the reference delineations (pink). For case 1, the mean ± 1σ of the DSC for the nodal and CTV vaginal cuff was 0.81 ± 0.03 (range: 0.68--0.86) and 0.60 ± 0.09 (range: 0.42--0.79), respectively. The HD with a unit of mm for the nodal and CTV vaginal cuff was 18.6 ± 6.3 (range: 10.9--32.6) and 24.7 ± 6.0 (range: 10.6--37.9), respectively. For case 2, the mean ± 1σ for the DSC was 0.81 ± 0.04 (range: 0.71--0.87) and 0.54 ± 0.14 (range: 0.23--0.78), respectively. The HD for the nodal and CTV vaginal cuff was 21.6 ± 10.4 (range: 12.3--83.4) and 32.4 ± 13.5 (range: 14.5--56.0), respectively. All treatment plans were finally accepted, with resubmissions required for 10 of the 47 institutions, although 11 major deviations were observed. Notably, seven cases were found to have a major deviation of delineation, particularly for the CTV vaginal cuff, or the submitted dose distributions did not meet the protocol requirements. For instance, a cold spot emerged inside the primary lesion (Fig. [4](#Fig4){ref-type="fig"}a). In the revised treatment plan (Fig. [4](#Fig4){ref-type="fig"}b), adequate dose coverage to the PTV was achieved. A broadening of 40 Gy in the bowel and the bladder region was also noted (Fig. [4](#Fig4){ref-type="fig"}c). In the revised treatment plan (Fig. [4](#Fig4){ref-type="fig"}d), these organs were spared from the 40 Gy dose. In another two cases, the PTV margin did not comply with the protocol. The two remaining cases had an incorrect PTV due to the presence of tiny structures in the nodal CTV (Fig. [4](#Fig4){ref-type="fig"}e). This might have been caused by an operational mistake in delineations, which results in an unnecessary treated region, as indicated by the white arrow in the figure. The color wash was displayed with the 95% dose level. In the revised plan (Fig. [4](#Fig4){ref-type="fig"}f), the PTV and dose distributions were corrected by erasing the tiny structure in the CTV. Additional file [1](#MOESM1){ref-type="media"}: Figure S1 shows the boxplots for the dose-volume histogram (DVH) results for 94 treatment plans in each case with the dose and dose-volume criteria (triangle marker). As shown in the figure, the D~98%~ and D~95%~ of the PTV was greater than the required criteria "per protocol," and the dose coverage of PTV in IMRT could be achieved. Additionally, almost all of the institutions succeed in preventing emergence of high doses to the bowel, including the overlap region of the PTV. This was because the upper quartile of the maximum dose in this region was lower than the global maximum dose. Additionally, it was observed that the lower quartile in almost all of the critical organs could be lower than "per protocol".Fig. 3CTVs for (**a**) nodal and (**b**) vagina cuff from the 47 institutions in case 1. The reference delineation is shown in pinkFig. 4Revised treatment plan (**b**, **d**, **f**) for the (**a**) emergence of a cold spot (≤95% dose). (**b**) broadening of 40 Gy in the bowel and the bladder region, and (**e**) wrong PTV due to the presence of tiny structures resulting from an operational mistake in delineations with a color wash at a 95% dose level, PTV(yellow), and CTV (pink, only Fig. 4e and f)

Discussion {#Sec7}
==========

The dummy-run in clinical trials is essential to ensure the quality of the study and to provide opportunities for early understanding of the protocol concept for participating institutions. Continuing education is important, and a dummy-run can help determine misinterpretations of the protocol before patient enrollment. Dummy-run studies have been reported from the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC) \[[@CR20]--[@CR25]\]. For instance, variations in the target volume and OAR definitions in head and neck cancer, lung, and prostate cancer were observed \[[@CR20]--[@CR23]\]. Generally, they concluded that a strict quality assurance procedure should be followed for radiotherapy. Meanwhile, only performing a dummy-run is inadequate for quality assurance (QA), although this is a limitation of this study. It is emphasized that individual case reviews are also encouraged to observe protocol variations \[[@CR24], [@CR25]\].

Regarding a dummy-run using the common CT dataset, the inter-observer error for delineations can be quantitatively evaluated. Eminowicz et al. demonstrated wide inter-observer variations in delineation of the CTV for definitive radiotherapy in cervical cancer \[[@CR26]\] and its dosimetric impact \[[@CR27]\]. In this study, the DSC and HD were used to quantitatively evaluate deviations of delineations from the reference. These metrics have been widely used as a standard tool. The DSC can be derived from the relative overlap area, while the HD can be calculated to quantitatively evaluate maximum gross deviations in surface dimensions. These metrics in this study showed that the DSC in the CTV vaginal cuff was lower than that in the nodal CTV for both cases. Additionally, the DSC for case 2 was lower than that for case 1. Similarly, the HD in the CTV vaginal cuff was greater than the nodal CTV. There are several possible reasons for the poorer agreement in the CTV vaginal cuff than in the nodal CTV. Some institutions did not notice small metallic markers inserted in the vaginal vault, and case 2 had moderate amount of ascites that made it difficult to define the CTV vaginal cuff. Meanwhile, because the nodal CTV is generally determined by the vascular structures, muscle, and bone, it is easier to delineate the nodal CTV than the CTV vaginal cuff.

In our previous study \[[@CR17]\], the CTV vaginal cuff showed greater inter-fractional variations in the SI and AP direction than RL. For instance, the 95th percentile of uncertainty of vaginal clips in RL, SI, and AP was 0.3, 0.7, and 1.2 cm, respectively. In this, study, it was observed that the vaginal cuff with a high risk of local recurrence had large uncertainties in delineations. Therefore, not only an adequate PTV-CTV margin, but also accurate delineations in the vaginal cuff is indispensable to prevent local recurrences in IMRT. The dummy-run test can effectively achieve the goal.

The JCOG1402 dose and dose-volume criteria were appropriate to achieve clinically acceptable treatment plans. These criteria could be established from the collected data using the DVH from the five representative institutions. In the process of developing the criteria, the previously published compliance data of the RTOG 0418 \[[@CR28]\] were taken into account. i.e., the criteria in rectum and bladder were relaxed in the JCOG1402. Additionally, these criteria were modified by the clinical perspectives as follows: the secondary endpoint of JCOG1402 is to show the reduction of GI toxicity compared with 3DCRT historical control data. Therefore, a high dose in the bowel should be avoided, e.g., the maximum dose in the whole bowel bag, including the overlap of the PTV, should be less than 110% of the prescribed dose (Table [1](#Tab1){ref-type="table"}). Moreover, a median dose is applied to the prescribed dose in the PTV. Therefore, dose coverage to the PTV should be carefully applied. In particular, the cold spot within the CTV vaginal cuff should be avoided because the lesion is considered as having a high risk of recurrence. A cold spot is possibly caused by strict dose constraints in the critical structures in optimization. Thus, not only constraint of D~98%~ and D~95%~ in the PTV, but also the ideal dose distributions (Fig. [1](#Fig1){ref-type="fig"}a) are provided in this protocol to retain a dose coverage equivalent to that in 3DCRT. A dose level of 40 Gy must be spared in the bowel region (Fig. [1](#Fig1){ref-type="fig"}c). Isohashi et al. reported that V~15--45\ Gy~ in the small bowel loops had high accuracy to predict GI complications, and multivariate analysis indicates V~40\ Gy~ in the small bowel loops as an independent predictor of chronic GI complications \[[@CR5]\]. By providing not only the dose and dose-volume criteria, but also the ideal dose distribution for the 95, 105%, and 40 Gy dose level to participating institutions, we could effectively standardize the treatment quality in the JCOG1402 protocol.

The dummy-run demonstrate trends of deviation from the protocol, and also provided information which could lead to standardizing plan quality in the JCOG 1402. Such helpful information has been fed back to participating institutions through specific face-to-face meetings which were held eight times between November 2016 and June 2018. In addition, the QA criteria established from the dummy-run process are used in the individual case reviews for patients entered in the JCOG1402.

Conclusions {#Sec8}
===========

The dummy-run test in postoperative uterine cervical cancer demonstrated substantial deviations in the delineations, particularly for the CTV vaginal cuff. The analysis data could provide helpful information on delineation and planning, allowing standardization of IMRT planning for postoperative uterine cervical cancer.

Additional files
================

 {#Sec9}

Additional file 1:**Figure S1**. DVH criteria and the box-plots with a bar of range for 94 treatment plans in two cases: Case 1: (a) and (b), Case 2: (c) and (d). 100% of dose and volume means the prescribed dose of 50.4 Gy and a whole volume of a structure, respectively (DOCX 46 kb) Additional file 2:**Table S2.** Assessed categories in the central review. (DOCX 16 kb)
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